Generator based therapeutic radiopharmaceutical production for targeting of fibroblast activation protein (FAP) KU Leuven
Pancreatic ductal adenocarcinoma (PDAC) is the most common malignant tumour of the pancreas. It is highly aggressive and rapidly fatal with a five-year survival rate of <5%. Effective screening is not available for PDAC, and most patients present with locally advanced (30%-35%) or metastatic
(50-55%) disease at diagnosis. Current chemotherapies are ineffective as the pancreatic tumours present a complex and highly obstructive tumour ...